The OncLive Immunotherapy in Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in lung cancer. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment in non–small cell lung cancer and small cell lung cancer.
April 4th 2024
Data from the phase 2 KICKSTART trial of tomivosertib plus pembrolizumab do not support the combination's use in patients with non–small cell lung cancer.
Immunotherapy/Chemo Combos Remain Go-To Option in Growing Small Cell Lung Cancer Paradigm
Chemoimmunotherapy is the new frontline standard of care for patients with small cell lung cancer, and other novel agents, such as, bispecific T-cell engagers are in the pipeline and gaining momentum for those who experience disease progression.
Cemiplimab/Chemo Represents New Frontline Option for Advanced NSCLC Without Actionable Mutations
October 4th 2021Miranda Gogishvili, MD, discusses the rationale for examining cemiplimab plus platinum-doublet chemotherapy as a frontline treatment in patients with advanced NSCLC and key findings from the phase 3 EMPOWER-Lung 3 trial.
Adjuvant treatment with atezolizumab led to an improvement in disease-free survival and time to locoregional and distant relapse compared with best supportive care in prespecified subgroups of PD-L1–positive patients with stage II to IIIA NSCLC, according to exploratory findings from the phase 3 IMpower010 trial.
Frontline I-O Monotherapy Versus Combination Therapy for PD-L1+ Stage IV NSCLC
Drs Roy S. Herbst and Sandip P. Patel comment on patient candidacy for immunotherapy as monotherapy to treat PD-L1+ metastatic non–small cell lung cancer versus chemoimmunotherapy.
Frontline Treatment of PD-L1+ Stage IV NSCLC: Cemiplimab
Roy S. Herbst, MD, PhD, of Yale Cancer Center, highlights treatment advances in stage IV non–small cell lung cancer, including cemiplimab as frontline monotherapy based on EMPOWER-Lung 1.
4-Year Findings Confirm Long-Term Benefit for Nivo/Ipi in First Line for mNSCLC
June 4th 2021The combination of nivolumab and ipilimumab continued to provide a durable, long-term overall survival benefit compared with chemotherapy after 4 years for patients with advanced non‒small cell lung cancer regardless of PD-L1 expression or histology.
Sugemalimab Shows Prolonged PFS in Stage III NSCLC
The investigational PD-L1 inhibitor sugemalimab prolonged progression-free survival in patients with locally advanced, unresectable stage III non–small cell lung cancer without disease progression after concurrent or sequential chemoradiation.
EU Panel Recommends Nivolumab/Ipilimumab in Frontline Unresectable Malignant Pleural Mesothelioma
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the combination of nivolumab and ipilimumab as a frontline treatment for adult patients with unresectable malignant pleural mesothelioma.
Durvalumab Use Differs in Real-World, PACIFIC Stage III NSCLC Populations
More patients with stage III non–small cell lung cancer received sequential chemoradiation and delayed the time to durvalumab treatment in a real-world setting compared with those enrolled on the phase 3 PACIFIC trial.
FDA Will Reassess 6 Immunotherapy Accelerated Approvals
March 12th 2021Six indications for immune checkpoint inhibitors granted under the FDA’s accelerated approval process that later failed confirmatory clinical trials are being reassessed as the agency continues an industry-wide evaluation of the pathway.
Borghaei Breaks Down Choices in Immunotherapy Approaches in Lung Cancer
February 8th 2021With the emergence of multiple immunotherapy approaches in recent years, the decision of whether to use a single agent, to pair it with chemotherapy, or to pair it with another immunotherapy agent has come to the forefront of treatment.
Ceralasertib/Durvalumab Combo Shows Efficacy in NSCLC Following Anti–PD-L1 Therapy
February 3, 2021 - The combination of ceralasertib plus durvalumab improved overall response rate in patients with non‒small cell lung cancer who progressed on an anti-PD-1/PD-L1 therapy.
Pembrolizumab/Ipilimumab Combo Does Not Improve Survival, Shows Higher Toxicity in PD-L1+ NSCLC
January 29, 2021 - Pembrolizumab plus ipilimumab did not improve survival and had higher rates of toxicity versus pembrolizumab monotherapy as a first-line treatment for patients with metastatic non–small cell lung cancer who had a PD-L1 tumor proportion score of 50% or greater, and did not harbor EGFR or ALK aberrations.